bims-fragic Biomed News
on Fragmentomics
Issue of 2026–02–15
five papers selected by
Laura Mannarino, Humanitas Research



  1. Cell Genom. 2026 Feb 06. pii: S2666-979X(26)00004-2. [Epub ahead of print] 101142
      Cell-free DNA (cfDNA) end motifs serve as fragmentomics biomarkers for cancer. Prior studies primarily focused on 5' ends, whereas 3' ends were overlooked due to artifactual modification in existing sequencing protocols. We utilized single-stranded library preparation ("2-end sequencing") to assess the native 5' and 3' end motifs (EM5 and EM3, respectively). Additionally, we demonstrated diagnostic power from the nucleotide motifs located immediately upstream and downstream of 5' and 3' ends, named pre-end motifs (PREMs) and post-end motifs (POEMs). These fragmentomics markers collectively achieved an area under the curve (AUC) of 0.95 for hepatocellular carcinoma (HCC) detection. Fragmentomics-based methylation analysis of 3' ends (3' FRAGMA) improved detection of HCC (AUC: 0.97). We further developed "4-end sequencing" to interrogate both ends of both strands of a double-stranded cfDNA molecule, enhancing fragmentomics-based cancer detection. Holistic end profiling adds to the armamentarium of liquid biopsy and sheds light on the biology of cfDNA fragmentation.
    Keywords:  cancer detection; end motifs; fragmentomics; noninvasive
    DOI:  https://doi.org/10.1016/j.xgen.2026.101142
  2. Nat Commun. 2026 Feb 14.
      Cell-free DNA (cfDNA) consists of degraded DNA fragments released into body fluids. Its genetic and pathological information makes it useful for prenatal testing and early tumor detection. However, the mechanisms behind cfDNA biology are largely unknown. In this study, for the first time, we conduct a genome-wide association study (GWAS) to explore the genetic basis of cfDNA end motif frequencies, termed cfGWAS, in 28,016 pregnant women. We identify 15 study-wide significant loci, including the well-known cfDNA-related genes DFFB and DNASE1L3, as well as novel genes potentially involved in cfDNA biology, such as PANX1 and DNASE1L1. The findings are further verified through three independent GWAS studies and experimental validation in knockout mice and cell lines. Subsequent analyses reveal strong causal relationships of leukocytes, especially neutrophils, with cfDNA features. In summary, we introduce the cfGWAS, revealing the genetic basis of cfDNA biology on a genome-wide scale. Novel knowledge uncovered by this study promises to revolutionize liquid biopsy technology and lead to potential new drugs targeting certain diseases. Given that millions of cfDNA whole genome sequencing data have been generated from clinical testing, the potential of this paradigm is enormous.
    DOI:  https://doi.org/10.1038/s41467-025-67940-w
  3. Front Immunol. 2026 ;17 1705156
       Background: Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately detect CRC.
    Methods: 573 individuals from Sir Run Run Shaw Hospital, two community healthcare centers and three additional medical centers, were collected between April 1, 2023, and December 12, 2025. Participants were divided into training, internal validation, and external validation cohorts. A variety of cfDNA fragmentomic features were analyzed and incorporated into machine learning models. The models were evaluated using 10-fold cross-validation and assessed for accuracy, sensitivity, specificity, and AUC values. We also performed differential analysis of key genomic features, such as Alu elements and long terminal repeats (LTRs), between benign and malignant CRC samples.
    Results: The machine learning algorithm demonstrated robust discriminative performance across all datasets using generalized linear modeling (GLM), achieving AUC values of 0.959 (training set), 0.979 (internal validation cohort), and 0.959 (external validation cohort). Notably, the model exhibited particularly strong classification accuracy for advanced-stage colorectal cancer (CRC). Comparative cfDNA profiling revealed distinct molecular signatures between benign and malignant samples: benign samples were characterized by elevated frequencies of Alu elements and long terminal repeats (LTRs), whereas malignant samples showed distinct end motif profiles, characterized by the significant enrichment of specific 4-mer end motifs. These findings suggest that these molecular features may serve as potential biomarkers for malignancy detection.
    Conclusion: This study demonstrates that cfDNA fragmentomic profiling, particularly differential patterns of Alu and LTR elements, effectively discriminates benign from malignant colorectal lesions. These findings validate the clinical utility of repetitive element analysis and provide a foundation for developing improved non-invasive CRC diagnostics through machine learning approaches incorporating genomic features.
    Keywords:  Alu elements; cell-free DNA; colorectal cancer; early detection; machine learning
    DOI:  https://doi.org/10.3389/fimmu.2026.1705156
  4. J Invest Dermatol. 2026 Feb 06. pii: S0022-202X(26)00079-5. [Epub ahead of print]
      Circulating cell-free DNA (cfDNA) fragmentomics-the analysis of cfDNA fragment-length profiles-has been explored as a biomarker across cancers, but evidence in melanoma is limited. We conducted a longitudinal prospective study of 235 AJCC stage II-IV melanoma patients (549 plasma samples) and 11 phenotypic high-risk healthy controls, quantifying six fragment-size ranges by routine capillary electrophoresis. Linear mixed-effects modelling and ROC analyses evaluated associations with disease status; time-dependent ROC and mixed-effects Cox regression assessed prognostic value in resected patients. Active-disease samples showed a fragmentation shift: enrichment and increased heterogeneity of short (20-150 bp) and short-dinucleosome (250-320 bp) fragments, with depletion of mononucleosome fragments (160-180 bp), consistent with tumour-associated nuclease/chromatin processing. Discrimination of active disease versus disease-free samples was modest (AUC up to 0.64), comparable to serum S100 (AUC 0.68) and higher than LDH (AUC 0.60). In resected patients, 250-320 bp variability and short-fragment ratios predicted relapse-free and distant-metastasis-free survival from blood draw (HR ≈ 1.5-2.4 per 1 SD increase) after clinical adjustment, with strongest performance over ∼3-6 months. Correlations with S100/LDH were weak, supporting independent biological information. Low-cost electrophoresis-based fragmentomics captures clinically meaningful shifts and provides complementary short-term prognostic information, supporting integration into higher-resolution or multimodal cfDNA assays for risk-adapted follow-up.
    Keywords:  capillary electrophoresis; circulating tumour DNA; liquid biopsy; metastasis; survival analysis
    DOI:  https://doi.org/10.1016/j.jid.2026.01.030